ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TEVA Teva Pharmaceutical Industries Ltd

14.135
0.035 (0.25%)
Last Updated: 15:31:00
Delayed by 15 minutes
Name Symbol Market Type
Teva Pharmaceutical Industries Ltd NYSE:TEVA NYSE Depository Receipt
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.035 0.25% 14.135 14.19 13.94 13.99 1,565,305 15:31:00

Teva to Present at the Cowen & Company 38th Annual Healthcare Conference

12/03/2018 12:40pm

Business Wire


Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 38th Annual Healthcare Conference in Boston, MA.

 

When:

Tuesday, March 13, 2018 at 11:20 AM ET  

Who:

Michael McClellan, EVP & Chief Financial Officer Teva Pharmaceutical Industries Ltd.  

Where:

http://wsw.com/webcast/cowen46/teva

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s Website at http://ir.tevapharm.com.

 

About Teva

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion.

Teva Pharmaceutical Industries Ltd.IR ContactsUnited StatesKevin C. Mannix, 215-591-8912Ran Meir, 215-591-3033orIsraelTomer Amitai, 972 (3) 926 7656orPR ContactsUnited StatesKaelan Hollon, 202-412-7076orIsraelYonatan Beker, 972 (54) 888 5898

1 Year Teva Pharmaceutical Indu... Chart

1 Year Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

Your Recent History

Delayed Upgrade Clock